title: Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods.
abstract: A large survey of antimicrobial resistance of Helicobacter pylori was performed in France in 2014: 984 patients were enrolled by 75 gastroenterologists all over the country. Among the 783 patients who had never received eradication treatment before, 266 (33.9%) were H. pylori positive. The strains showed a high rate of clarithromycin resistance (22.2%), moderate rate of resistance to levofloxacin (15.4%) and high rate of resistance to metronidazole (45.9%). In all, 187 patients had received previous treatment, of which 115 were H. pylori positive with very high resistance to clarithromycin (73.9%) and metronidazole (78.3%). None of the patients receiving PYLERA (Bismuth salt-Tetracycline HCl-Metronidazole) proton-pump inhibitor developed resistance to tetracycline. A real-time PCR applied to gastric biopsy specimens detected all the cases that were positive by culture as well as 30 additional cases. A good correlation was found between the clarithromycin resistance detected by phenotypic methods and the associated mutations for clarithromycin resistance, which has continued to increase in the last decade but at a lower rate than previously observed.
authors.affiliation: Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, INSERM U853, Bordeaux, France.
authors.forename: A
authors.initials: A
authors.lastname: Ducournau
authors.affiliation: Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, INSERM U853, Bordeaux, France.
authors.forename: L
authors.initials: L
authors.lastname: Bénéjat
authors.affiliation: Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, INSERM U853, Bordeaux, France.
authors.forename: E
authors.initials: E
authors.lastname: Sifré
authors.affiliation: Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, INSERM U853, Bordeaux, France.
authors.forename: E
authors.initials: E
authors.lastname: Bessède
authors.affiliation: Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, INSERM U853, Bordeaux, France.
authors.forename: P
authors.initials: P
authors.lastname: Lehours
authors.affiliation: Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, INSERM U853, Bordeaux, France. Electronic address: francis.megraud@chu-bordeaux.fr.
authors.forename: F
authors.initials: F
authors.lastname: Mégraud
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D005260:Female; D005602:France / Q000453:epidemiology; D005838:Genotype; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D016480:Helicobacter pylori / Q000145:classification / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009154:Mutation; D010641:Phenotype; D011159:Population Surveillance; D015995:Prevalence; D012338:RNA, Ribosomal, 23S / Q000235:genetics
chemical_list: D000900:Anti-Bacterial Agents; D012338:RNA, Ribosomal, 23S
keywords: 23S rDNA mutation; Antimicrobial susceptibility testing; Clarithromycin; Levofloxacin; PYLERA; Tetracycline